BCL-xL is a therapeutic target for SCLC and NSCLC (156, 157), an anti-apoptotic protein belongs to the B cell lymphoma (BCL) family of cell survival proteins, and BCL-xL-overexpressed cancer cells permit NDV infection and viral syncytium formation required for viral spread (Figure 3) (157). The gene discussed is BCL2L1; the disease is small cell lung carcinoma.